Noopept: The Definitive Guide

What is noopept?

Noopept is a synthetic proline-glycine derivative also called omberacetam or GVS-111. It is often grouped with racetams in product catalogs, though its chemical structure is different. It has no nutritional role, deficiency state or established intake requirement.

The strongest accessible human record is a 2009 comparison with piracetam. Fifty-three outpatients with mild cognitive disorders of vascular or post-traumatic origin were randomized to one of the two active medicines; there was no placebo and no reported masking. Only 41 completed 56 days. Both groups improved on several measures, while the authors reported some noopept advantages. That design cannot show how much improvement exceeded time, practice effects, expectation or regression to the mean. [1]

A second open prospective report enrolled 60 people after ischemic stroke and reported better cognitive measures after two months at 20 mg/day. It adds a different clinical population but does not establish healthy-user benefit. [2]

Typical Noopept Research Protocols

The repeated 20 mg/day total belongs to these clinical records, not to an established consumer protocol. The 2009 paper provides 10 mg twice daily. The post-stroke abstract does not, so this guide does not assume the same schedule.

Product identity

Record omberacetam/noopept name, manufacturer, lot, dosage form and whether the exact finished product is authorized.

Administration

Keep amount each time, daily total, route and timing separate; intranasal use is not represented by these oral clinical reports.

Outcome and safety

Define the cognitive or functional outcome and record sleep, irritability, blood pressure and treatment changes.

What is noopept commonly used for?

Vascular and post-traumatic cognitive disorders

The 2009 full report included 37 people with vascular-origin organic emotional-lability or asthenic disorder and 16 with post-concussion syndrome. Thirty-one received noopept and 22 received piracetam. The paper reported within-group cognitive and symptom changes and some CGI advantages for noopept, while cognitive-scale effects were described as comparable between medicines. [1]

The meaningful limitation is the missing placebo. Randomization between two active treatments does not reveal whether either medicine outperformed no treatment. Attrition also mattered: 12 of 53 did not complete, including four in the noopept group and eight in the piracetam group.

Mild cognitive impairment after stroke

The 2011 open prospective report included 60 people who had experienced stroke within the prior 12 months. The abstract reports improved MMSE and lateral and categorical word-association measures after two months at 20 mg/day compared with controls. It does not provide group counts, allocation, masking, formulation or administration frequency. [2]

Healthy cognition

Neither human report studied healthy students, professionals or older adults without neurologic impairment. No strong placebo-controlled trial establishes better memory, focus or learning in healthy users. A companion EEG report described alpha, beta and delta rhythm changes in impaired patients, but EEG patterns are not proof of improved daily function and may overlap the main clinical program. [3]

What do the mechanism studies show?

Rat studies report changes in hippocampal NGF and BDNF mRNA, and rat hippocampal-slice work implicates α7 nicotinic acetylcholine receptors on interneurons. These are useful mechanistic hypotheses. They do not establish a human memory effect, clinical dose or need for a choline co-product. [4], [5]

A 2021 inflammation paper was formally retracted. Its findings are excluded from this guide rather than used as positive mechanism evidence. [7]

How do forms and labels differ?

Names include noopept, omberacetam, GVS-111 and N-phenylacetyl-L-prolylglycine ethyl ester. An authorized tablet in one country, an imported capsule, bulk powder and an online nasal preparation are not interchangeable. The clinical records here used oral treatment; they do not validate an intranasal schedule.

In a laboratory study of ten cognitive-enhancement products labeled with unapproved drug names, declared omberacetam was sometimes absent and undeclared drugs were present. A label or certificate cannot guarantee equivalence to the studied medicine. [6]

How should noopept be stored?

Follow the pharmacy label for any lawfully dispensed product. Keep it in the original labeled container, dry, away from heat and inaccessible to children. Do not store unidentified powder beside food or routine supplements. Storage cannot fix substitution, contamination or inaccurate strength.

What does the human evidence show?

What are the risks and interactions?

In the 31-person noopept arm, four participants stopped early: one moved, one reported lack of benefit and two had increased blood pressure that required treatment. Table 3 lists 21 adverse events and explicitly allows multiple events per person. It includes seven sleep-disturbance events, four increased-blood-pressure events and three irritability events. These are event counts, not percentages of participants. [1]

The study is too small and short to exclude uncommon or delayed harm. Because noopept has central nervous system activity and blood-pressure changes occurred, review stimulant medicines, modafinil or adrafinil, decongestants, high-caffeine products, other nootropics, antihypertensives and sedatives with a clinician or pharmacist. Evidence does not establish that choline prevents headache or other adverse effects.

Pregnancy, breastfeeding, childhood, kidney or liver disease, uncontrolled hypertension, cardiovascular disease, seizure history, bipolar or psychotic illness and perioperative use deserve clinical review. Seek urgent care for severe headache with neurologic symptoms, chest pain, fainting, seizure, severe agitation or confusion, or allergic symptoms.

What is the legal and regulatory status?

FDA’s 2019 Peak Nootropics warning letter names Noopept and states the cited marketed product was not a dietary supplement or conventional food. [8] Australia names omberacetam under the Schedule 4 prescription-only racetam entry. [9] OPSS includes omberacetam/Noopept among racetam drugs prohibited as supplement ingredients for U.S. service members. [10]

In Canada, verify any claimed medicine through the Drug Product Database and any claimed natural health product through the Licensed Natural Health Products Database. An online listing is not proof of a DIN or NPN. [11]

Noopept is not named in WADA’s 2026 S6 stimulant list, but omission by name is not athlete clearance. S0 can apply to pharmacological substances without current governmental therapeutic approval. Athletes should obtain current sport- and jurisdiction-specific advice.

When should use stop?

Stop an unverified product and seek advice for a new or sustained blood-pressure rise, severe headache, insomnia, agitation, marked irritability, mood change or neurologic symptoms. Do not start or stop a lawfully prescribed cognitive medicine without the prescriber.

What should be monitored?

In medical care, define the cognitive and functional endpoint before treatment. Record baseline performance, each oral administration, adherence, blood pressure when clinically directed, sleep, irritability, other medicines and reasons for stopping. Reassess whether change exceeds practice effects and ordinary fluctuation.

The 2009 study demonstrates why participant flow matters: a headline about relative efficacy is incomplete without the 41/53 completion count and the reasons for withdrawal.

What does community experience add?

Public reports may surface irritability, insomnia, headaches, subjective focus changes and route-specific problems. Product identity, co-use and expectation are rarely controlled. No systematic current community sample was assembled, so this guide reports no consensus dose, intranasal schedule, cycle, response rate or required choline stack.

How does noopept compare with related options?

Common questions

Is noopept a peptide or a racetam?

It is a synthetic proline-glycine derivative often grouped with racetams commercially, but it is not a nutritional peptide or classic racetam molecule.

Did the main human study have a placebo?

No. It compared noopept with piracetam. Both groups’ changes therefore cannot show how much exceeded no treatment. [1]

How many people completed the main study?

Forty-one of 53 completed 56 days. Four noopept participants and eight piracetam participants stopped early. [1]

Is 10 mg twice daily a recommended dose?

It is the exact oral schedule from one small impaired-population study, not a validated healthy-user recommendation.

Does noopept raise blood pressure?

The main report recorded four increased-blood-pressure events in the noopept arm, including two significant events that led to withdrawal and treatment. The small study cannot estimate an individual risk precisely. [1]

Should it be used intranasally?

The human studies summarized here used oral treatment. They do not establish an intranasal formulation, amount, absorption profile or safety.

Does it require choline?

No controlled evidence establishes a universal choline requirement or proves that co-use prevents adverse effects.

Was a noopept study retracted?

Yes. A 2021 persistent-inflammation animal paper was retracted and is excluded from this evidence synthesis. [7]

Glossary

Plain explanations of noopept evidence terms.

Active comparator

A study group receiving another active treatment rather than placebo or no treatment.

Attrition

Participants who stop before study completion; unequal or substantial loss can change interpretation.

MMSE

A brief global cognitive screening test that is sensitive to practice and clinical context.

Omberacetam

International nonproprietary name used for noopept.

Adverse-event count

Number of events; one participant may contribute more than one, so it is not automatically a participant percentage.

Retraction

Formal withdrawal of a paper from the reliable scientific record.

Schedule 4

Australia’s prescription-only scheduling category.

How this guide was researched

Seven PubMed records were checked live through NCBI EFetch for title, author, journal, volume, issue, pages, DOI and descendant publication-status notices. The complete 2009 report supplied participant flow, exact twice-daily administration, endpoints and Table 3 safety events. The 2011 indexed and publisher abstracts supplied the post-stroke design and exposed its missing fields. Official FDA, TGA, OPSS and WADA sources supplied jurisdiction-specific context.

Explore the sources

Related guides

• Piracetam
• Aniracetam
• Oxiracetam
• Phenylpiracetam
• Nootropic compounds

Editorial note

This guide uses the full clinical report for participant flow, administration and safety rather than repeating summary claims. It excludes a retracted paper and keeps the absence of placebo central to the conclusion.